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Abstract
Background: The possibility that allogeneic hematopoietic stem cell transplantation performed across
the ABO blood group-barrier is associated with an increase of graft-versus-host disease, in particular
endothelial damage, has not been elucidated so far. For this reason, we investigated the level of
endothelial cell chimerism after allogeneic hematopoietic stem cell transplantation in order to delineate
the role of hematopoietic stem cells in endothelial replacement. Design and Methods: The frequency of
donor-derived endothelial cells was analyzed in 52 hematopoietic stem cell transplantation recipients, in
22 normal skin biopsies, in 12 graft-versus-host disease affected skin samples, various tissues from 5
autopsies and 4 secondary solid tumors by ABH immunohistochemistry, XY fluorescence in situ
hybridization and short tandem repeat analysis of laser captured endothelial cells. Results: Skin biopsies
from two minor ABO-incompatible (i.e. O in A) transplanted patients showed 3.3% and 0.9% H
antigen-positive donor-derived endothelial cells by ABH immunohistochemistry. Tumor biopsies from
two recipients showed 1.2% and 2.5% donor-derived endothelial cells by combined
immunohistochemistry/ fluorescence in situ hybridization. All other skin samples, heart, liver,
bone-marrow, and tumor tissues failed to reveal donor-type endothelial cells up to several years after
ABO-incompatible hematopoietic stem cell transplantation. Conclusions: Endothelial cell replacement
by bone marrow-derived donor cells after allogeneic hematopoietic stem cell transplantation is a rare
event. It does not seem to represent a major mechanism of physiological in vivo blood vessel formation,
tumor neo-angiogenesis, and vascular repair after graft-versus-host disease episodes or acceptance of
ABO-incompatible grafts.
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Background: The possibility that allogeneic hematopoietic stem cell transplantation performed across
the ABO blood group-barrier is associated with an increase of graft-versus-host disease, in particular
endothelial damage, has not been elucidated so far. For this reason, we investigated the level of
endothelial cell chimerism after allogeneic hematopoietic stem cell transplantation in order to delineate
the role of hematopoietic stem cells in endothelial replacement. Design and Methods: The frequency of
donor-derived endothelial cells was analyzed in 52 hematopoietic stem cell transplantation recipients, in
22 normal skin biopsies, in 12 graft-versus-host disease affected skin samples, various tissues from 5
autopsies and 4 secondary solid tumors by ABH immunohistochemistry, XY fluorescence in situ
hybridization and short tandem repeat analysis of laser captured endothelial cells. Results: Skin biopsies
from two minor ABO-incompatible (i.e. O in A) transplanted patients showed 3.3% and 0.9% H
antigen-positive donor-derived endothelial cells by ABH immunohistochemistry. Tumor biopsies from
two recipients showed 1.2% and 2.5% donor-derived endothelial cells by combined
immunohistochemistry/ fluorescence in situ hybridization. All other skin samples, heart, liver,
bone-marrow, and tumor tissues failed to reveal donor-type endothelial cells up to several years after
ABO-incompatible hematopoietic stem cell transplantation. Conclusions: Endothelial cell replacement
by bone marrow-derived donor cells after allogeneic hematopoietic stem cell transplantation is a rare
event. It does not seem to represent a major mechanism of physiological in vivo blood vessel formation,
tumor neo-angiogenesis, and vascular repair after graft-versus-host disease episodes or acceptance of
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Background
The possibility that allogeneic hematopoietic stem cell transplantation performed across the
ABO blood group-barrier is associated with an increase of graft-versus-host disease, in particular
endothelial damage, has not been elucidated so far. For this reason, we investigated the level of
endothelial cell chimerism after allogeneic hematopoietic stem cell transplantation in order to
delineate the role of hematopoietic stem cells in endothelial replacement. 
Design and Methods
The frequency of donor-derived endothelial cells was analyzed in 52 hematopoietic stem cell
transplant recipients, in 22 normal skin biopsies, in 12 skin samples affected by graft-versus-host
disease, various tissues from five autopsies and four secondary solid tumors by ABH immuno-
histochemistry, XY fluorescence in situ hybridization and short tandem repeat analysis of laser
captured endothelial cells. 
Results
Skin biopsies from two patients transplanted with minor ABO-incompatible grafts (i.e. O in A)
showed 3.3% and 0.9% H antigen-positive donor-derived endothelial cells by ABH immuno-
histochemistry. Tumor biopsies from two recipients showed 1.2% and 2.5% donor-derived
endothelial cells by combined immunohistochemistry/ fluorescence in situ hybridization. All
other skin samples, heart, liver, bone-marrow, and tumor tissues failed to reveal donor-type
endothelial cells up to several years after ABO-incompatible hematopoietic stem cell transplan-
tation.
Conclusions
Endothelial cell replacement by bone marrow-derived donor cells after allogeneic hematopoi-
etic stem cell transplantation is a rare event. It does not seem to represent a major mechanism
of physiological in vivo blood vessel formation, tumor neo-angiogenesis, vascular repair after
graft-versus-host disease episodes or acceptance of ABO-incompatible grafts. 
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Introduction
Transdifferentiation of hematopoietic stem cells into
non-hematopoietic tissue has received great attention in
transplantation medicine as a potential mechanism of tis-
sue repair.1 In 1965, Medawar2 hypothesized that long-
term acceptance of solid organ transplants may be the
result of replacement of their vascular endothelial cells by
recipient-type cells leading to an endothelial cell
chimerism. In particular, bone marrow-derived endothe-
lial progenitor cells may replace damaged graft endotheli-
um after rejection episodes. This hypothesis has been cor-
roborated both by animal models and data from human
transplants.3-9 However, there are also equivocal results
possibly due to the different methods used to detect
chimerism, pre-existing male chimerism in female donors
after giving birth to male children or receiving male blood
transfusions, and finally physiological differences in the
extent of chimerism in various organs and cell types.10,11
The concept of plasticity has also been questioned by the
finding that stem cells can fuse with other cells and mimic
the appearance of transdifferentiation; however this has
not been shown formally for endothelial cells.12,13
The occurrence of endothelial cell chimerism following
hematopoietic stem cell transplantation (HSCT) is like-
wise controversial. In theory, bone marrow-derived
donor-type endothelial cells may replace damaged host
endothelium in tissues affected by graft-versus-host dis-
ease (GVHD) as well as normal endothelium during phys-
iological cell replacement. In support of this notion donor
chimerism has been described in the endothelium of skin,
gut, heart and bone marrow in patients after HSCT.14-16
Furthermore, it was recently suggested that donor-
derived endothelial cells participate in endothelial repair
during the effector phase of acute GVHD,17 and donor-
derived endothelial cells were detected in 25% of sex-
mismatched skin biopsies following HSCT, especially in
patients with acute GVHD, and at later time points.18
Among others, ABH histo-blood group antigens
expressed on endothelial cells represent a potential target
for GVHD. Allogeneic HSCT is performed across the
ABO-blood group barrier in about 30-50% of patients.
Whether ABO-incompatibility affects the rate of GVHD,
overall survival, transplant-related mortality and relapse is
a matter of a longstanding debate. Recent studies showed
that minor and major ABO incompatibility can be associ-
ated with a higher incidence of GVHD and may also have
a negative impact on outcome.19-21 Endothelial replace-
ment and chimerism by donor bone marrow-derived cells
might play a role in ABO-incompatibility; theoretically it
could be a result of rejection and eventually favor the
development of ABO tolerance. 
Since previous studies often suffered from technical dif-
ficulties hampering reliable distinction between donor
and recipient endothelial cells, we meticulously investi-
gated the level of endothelial cell chimerism after allo-
geneic HSCT by using three different methods. After
ABO-incompatible HSCT, ABH antigen expression on the
vascular endothelium was analyzed by ABH immunohis-
tochemistry.22,23 In addition, tissues from gender-mis-
matched HSCT recipients, accounting for approximately
50% of patients undergoing allogeneic HSCT,19 were ana-
lyzed by fluorescence in situ hybridization (FISH) for X
and Y chromosomes. Finally, polymerase chain reaction-
based short tandem repeat (STR) analyses were per-
formed on selected samples using single laser-capture
micro-dissected endothelial cells to identify their donor or
recipient origin. Physiological endothelial cell turnover
was analyzed in normal skin, autopsy tissue, tissues
affected by GVHD and secondary tumor biopsies.
Design and Methods
Tissue sampling and immunohistochemistry
A total of 52 patients were included in this analysis; skin
punch biopsies were obtained from 22 of these patients in a
prospective manner during routine bone marrow punctures
before and after HSCT. In addition, diagnostic skin biopsies
from 21 patients suspected of having GVHD, nine tissue samples
from five autopsies, and four tumor biopsies were analyzed ret-
rospectively. The study protocol was approved by the local eth-
ical committee of the University Hospital Zurich (EK-951).
Immunohistochemical staining of ABH antigens and endothe-
lial cell markers was performed according to a previously pub-
lished protocol22 with monoclonal antibodies against A, B and H
antigens (Dako, Carpintera CA, USA) and against CD45, CD31
(PECAM-1), CD34 and von Willebrand factor (VWF). Further
details on the samples, patients’ characteristics, ABH antigen
staining and analysis of chimerism are provided in the Online
Supplementary Material.
Combined fluorescence in situ hybridization for X and Y
chromosomes and immunohistochemical staining for
von Willebrand factor
Tissue samples after gender-mismatched HSCT were ana-
lyzed by combined FISH and immunohistochemical staining for
the endothelial cell-specific marker VWF.24 Sections (4 μm) were
stained for X and Y chromosomes. The technical details of the
FISH and VWF-staining and methods of analysis are provided in
the Online Supplementary Material.
Short tandem repeat analysis
Single endothelial cells were captured out of cryostat sec-
tions previously stained for either CD45 (negative selection) or
VWF antigen (positive selection). Nuclei from 20-40 endothe-
lial cells per section were needed for complete STR amplifica-
tion. The technical details of STR analysis are provided in the
Online Supplementary Material. To determine donor- and recipi-
ent-specific patterns of STR loci, peripheral blood mononuclear
cells of the donor and the recipient were analyzed prior to
transplantation.
The respective numbers of skin, autopsy and tumor biopsies
that were tested with one or any combination of the three meth-
ods used to determine endothelial chimerism are summarized in
Online Supplementary Table S1.
Results
Persistence of recipient-type short tandem repeat 
patterns in skin endothelial cells after hematopoietic
stem cell transplantation
At the time of taking the skin biopsy, hematopoietic
chimerism was determined in peripheral blood samples in
34 out of the investigated 52 patients. Hematopoietic
donor-chimerism was 100% in 30 patients including the
two with low levels of donor endothelial chimerism (#25,
#28) shown below. Three patients had low levels [#16
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Table 1. Patients’ characteristics and evaluation of endothelial cell chimerism.
ABO Gender STR¶
Patient Age Disease Day* GVHD† R/D R‡ D‡ R/D R§ D§
Prospective skin biopsy study
1 32 CML 102 0/no A/O 46/21 0/14 m/m NA NA R
2 46 AML 151 I/no A/O 257/71 0/45 f/m 46 0 ND
3 43 CML 245 II/no A/O 84/29 0/27 f/m ND ND ND
4 39 CML 615 IV/no A/A 75/39 NA m/f ND ND ND
5 40 CML 103 0/no A/A 79/28 NA m/m NA NA ND
6 40 CML 102 I/no A/A 40/15 NA m/m NA NA ND
7 41 AML 381 I/ext. A/A 91/33 NA m/m NA NA ND
8 41 AML 192 0/ext. A/A 116/27 NA m/m NA NA ND
9 48 ALL 420 I/ext. A/A 74/23 NA m/f ND ND ND
10 51 ALL 181 0/no A/A 109/35 NA m/m NA NA ND
11 56 AML 264 I/no A/A 21/8 NA f/m ND ND ND
12 34 CML 94 II B/O 203/95 0/50 m/m NA NA ND
13 45 AML 547 0/no B/O 74/38 0/31 f/m 25 0 ND
14 52 AML 193 I/lim. B/O 49/13 0/15 m/m NA NA ND
15 41 AML 849 IV/no O/A 28/14 0/12 m/m NA NA R
16 27 MPS 100 0/no O/A 34/16 0/18 f/m 6 0 R
17 26 CML 718 II/ext. O/B 114/56 0/51 f/m 29 0 R
18 57 MPS 132 I/lim. O/B 59/49 0/45 m/f 7(8)** 0 R
19 20 ALL 189 I/ext. O/O 22/17 NA m/m NA NA ND
20 28 AML 100 I/lim. O/O 64/24 NA f/m ND ND ND
21 52 AML 101 II/ext. O/O 92/61 NA f/m ND ND ND
22 58 MM 51 II O/O 2,906/781 NA m/f 21** 0** ND
Retrospective skin biopsy study
23 41 CML 1915 III/no A/B 106/29 0/25 m/f 5§ 0** ND
24 15 AML 1928 II/lim. A/O 293/45 0/33 m/f 4(9) 0 ND
25 28 ALL 1552 I/lim. A/O 148/72 5/68 m/f 11** 0** ND
26 57 CLL 83 II A/O 273/87 0/41 f/m 19** 0** ND
27 31 CML 7 III A/O 23/3 0/3 m/f 10(12) 0 ND
28 48 MM 1001 II/lim. A/O 432/164 4/82 m/m NA NA ND
29 14 CML 613 II/ext. A/A 123/46 NA f/m 8** 0** ND
30 35 AML 918 II/ext. A/A 110/42 NA f/f NA NA ND
31 63 MM 94 III A/A 327/103 NA f/f NA NA ND
903 III/lim. A/A 1,111/463 NA f/f NA NA ND
32 35 ALL 1412 II/lim. B/O 418/142 0/35 m/f 29(12)** 0** ND
33 42 CML 195 I/no B/B 221/58 NA m/f 3** 0** ND
34 53 MPS 489 0/lim. O/A 44/26 0/22 m/m NA NA ND
35 30 ALL 999 II/ext. O/A 266/91 0/65 f/f NA NA ND
36 45 CML 34 I O/O 35/18 NA m/m NA NA ND
37 24 CML 1121 I/no O/O 92/69 NA f/m ND ND ND
38 44 CLL 866 0/lim. O/O 18/92 NA m/m NA NA ND
39 54 CLL 89 II O/O 117/19 NA m/m NA NA ND
40 28 CML 3476 II/ext. AB/A 579A/158 0/66 m/m NA NA ND
3476 II/ext. AB/A 442B/126 0/66 m/m NA NA ND
41 38 MDS 35 III AB/B 69A/33 0/12 m/m NA NA ND
35 III AB/B 35B/19 0/12 m/m NA NA ND
42 59 MDS 188 I/lim. AB/B 290A/84 0/50 m/f 19(24) 0 ND
188 I/lim. AB/B 336B/101 0/50 m/f NA NA ND
43 32 MM 1548 I/no AB/B 444A/106 0/73 m/m NA NA ND
1548 I/no AB/B 433B/109 0/73 m/m NA NA ND
Autopsy study
44 57 AML 96 IV A/O 577/267S 0/228S m/m NA NA ND
45 61 MM 145 IV/no B/A 1,950/665S 0/461S m/m NA NA ND
145 IV/no B/A 18,734/134H 0/14H m/m NA NA ND
145 IV/no B/A 974/78BM 0/13BM m/m NA NA ND
continued on the next page
(3%), #26 (8%), and #44 (5%)] and one patient [#33
(77%)] had high levels of remaining recipient hematopoi-
etic cells in the peripheral blood at the time of biopsy.
STR analysis was performed on DNA extracted from
vascular endothelial cells in skin biopsies from five
patients. In each case, seven or more highly polymorphic
STR loci, including the amelogenin locus, were success-
fully analyzed. All of the captured endothelial cells con-
tained DNA with a STR pattern matching the previously
analyzed STR pattern of the recipient and no donor
repeats could be detected (Table 1; Figure 1).
Unfortunately, the analysis of endothelial cells in the skin
biopsies of patients #25 and #28, who showed low levels
of donor-type endothelial cell chimerism by ABH antigen
staining, was unsuccessful because of poor DNA quality
in these formalin-fixed and paraffin-embedded biopsy
samples.
Persistence of recipient-type ABH antigen expression in
skin endothelial cells after hematopoietic stem cell
transplantation
Skin biopsies from 25 patients were evaluated for
endothelial cell chimerism by immunohistochemistry for
ABH antigens in the context of ABO-mismatched HSCT.
Normal skin was analyzed for ten patients and GVHD-
affected skin samples for 15 patients. 
As expected, ABH antigens were found on both
endothelial cells and erythrocytes of the dermal layers. In
general, the expression pattern of ABH antigens was com-
parable in all types of blood vessels, with the exception of
H antigen staining in biopsies from type O recipients,
where capillaries showed stronger expression than arteri-
oles and venules. On the other hand, H antigen staining
was weaker than A and B antigen staining. The granular
layer of the epidermis, sweat glands and hair follicles
were positively stained in about 80% of the samples.
Representative examples of ABH antigen staining in
skin biopsies and the average quantification of each recip-
ient group according to the different blood groups (i.e.
recipients of type A, B, O and AB) are shown in Figure 2.
Staining for the pan-leukocyte marker CD45, the
endothelial cell markers CD31, CD34 and VWF and addi-
tional hematoxylin/eosin (H/E) staining were performed
on serial sections in order to evaluate the presence of
leukocytes and the number of blood vessels in the tissue
sample in parallel. A median of 45 vessels (range, 3-781)
and 108 endothelial cells (range, 18-2,906) on every skin
biopsy section were analyzed for expression of ABH anti-
gens, resulting in a total of 11,282 counted endothelial
cells. In 23 out of 25 patients, the skin biopsies exclusively
showed recipient-derived vascular endothelial cells
(Figure 2E-H). The remaining two skin biopsies, derived
from recipients of minor ABO-incompatible grafts
(patients #25 and #28), exhibited low levels of donor-type
endothelial cells. In proportion to the total amount of
evaluated endothelial cells on the sections, these two
patients showed 3.3% and 0.9% of H antigen-positive
cells in the endothelial lining, respectively (Table 1). Both
patients suffered from limited chronic GVHD at the time
of the biopsy and had a history of mild acute GVHD
(grade I and II, respectively), but no histological signs of
skin inflammation or skin GVHD on the biopsy. 
Moreover, three out of ten patients after ABO-identical
HSCT (O in O 1; A in A 2) showed, in addition to their
own blood group type, aberrant B antigen (O in O and A
in A) or H antigen (A in A) expression in skin biopsies. 
Persistence of recipient-type X and Y chromosome
karyotype in skin endothelial cells after hematopoietic
stem cell transplantation
In situ hybridization for X and Y chromosomes con-
firmed the findings of ABH immunohistochemistry in
patients with gender-mismatched HSCT (Table 1; Figure
3A). Skin biopsies were available from 22 patients after
gender-mismatched HSCT. Chimerism was analyzed in
15 patients by combined immunohistochemistry for
VWF/FISH and was confirmed in eight patients by chro-
mogen in situ hybridization (CISH) analysis. Skin biopsies
derived from seven patients could not be analyzed due to
severely impaired tissue morphology. A total of 242
endothelial cells were counted with a signal of two chro-
mosomes in their nucleus in relation to 204 endothelial
cells which only displayed one X or the Y chromosome
due to a cross-sectioned nucleus. None of the endothelial
cells analyzed in this study had more than two sex chro-
mosomes in the nucleus, making cell fusion as potential
repair mechanism unlikely.
Recipient-type endothelial cells persisted in all skin
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46 39 NHL 350 IV/no O/A 14,256/94H 0/13H m/f 26 H ** 0 H ** ND
350 IV/no O/A 41/18BM 0/20BM m/f ND ND ND
47 44 CML 115 IV/no O/A ND ND m/f 20(20) H 0 H ND
48 60 AML 102 II O/A 12,456/81H 0/3H m/m NA NA ND
102 II O/A 246/27L 0/25L m/m NA NA ND
Tumor tissues
49 47 MM 181 II/ext. O/B 74/37 0/28 m/f ND ND ND
50 14 CML 12 years II/no A/A ND ND f/m 34 2 ND
51 12 AA 13 years 0/no A/A ND ND f/m 31 4 ND
52 41 CML 21 years 0/no O/O ND ND f/m 13 0 ND
*Days after HSCT. †Grade of GVHD (acute 0-IV; lim: chronic limited; ext: chronic extensive). ‡Number of ABH antigen-expressing endothelial cells shown as a ratio to the number of
counted blood vessels on the same tissue section. §Counted numbers of VWF-positive endothelial cells showing either XX (f: female), XY (m: male) karyotype or only the Y chromo-
some (indicated in brackets). **Results confirmed by CISH. S: skin, H:heart, BM: bone marrow, L: liver. ¶Type of STR pattern found. Patients showing endothelial cell chimerism are
highlighted in bold.  ALL: acute lymphatic leukemia,  AML: acute myelogenous leukemia, CML: chronic myelogenous leukemia, D: donor, MDS: myelodysplastic syndrome, MM: multiple
myeloma, MPS: myeloproliferative syndrome, NA: not applicable, ND: not determined due to technical limitations, NHL: non-Hodgkin’s-lymphoma, R: recipient.
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biopsies. In contrast, donor leukocytes were frequently
found in the perivascular areas, most likely representing
infiltrating donor leukocytes. The HSCT of patient #25
was gender-mismatched, and this patient showed 3.3%
donor-type endothelial cell chimerism by ABH antigen
staining (Table 1). However, evidence for donor-derived
endothelial cells was not detected with immunohisto-
chemistry/FISH or with CISH. 
Donor-type endothelial cell chimerism at a low level in
tumor neoangiogenesis after hematopoietic stem cell
transplantation
Finally, tumor samples from four patients were analyzed
for endothelial cell chimerism. One patient had an
extramedullary relapse of multiple myeloma after ABO-
incompatible HSCT (patient #49, B in O). In this case, ABH
immunohistochemistry of the tumor biopsy 181 days after
HSCT exclusively showed recipient-type H antigen expres-
sion on endothelial cells and none of the cells expressed
donor-type B antigen. Furthermore, three patients devel-
oped secondary carcinomas 12 to 21 years after ABO-iden-
tical, gender-mismatched HSCT and were analyzed for
endothelial cell chimerism by combined immunohisto-
chemistry/FISH. Low numbers of donor-derived endothe-
lial cells were detected in tumor vessels in two patients,
1.2% of the total amount of VWF-positive endothelial cells
in a mucoepidermoid carcinoma of the parotid gland
(patient #50; Figure 3B) and 2.5% in a papillary thyroid car-
cinoma (patient #51). In contrast, one patient with invasive
ductal carcinoma of the breast had no signs of donor-
derived endothelial cells (patient #52). In conclusion, the
large majority of endothelial cells in the investigated tumors
arose from the endogenous progenitor cell pool and not
from the transplanted hematopoietic stem cells. 
No evidence for donor-type endothelial cell chimerism
in autopsy-derived tissues after hematopoietic stem
cell transplantation
Post-mortem tissue was obtained from five patients.
Three patients died from grade IV acute GVHD (patients
#44, #45 and #46), one patient had general pancytopenia
and subsequently died of bronchiolitis obliterans and sub-
arachnoid hemorrhage (patient #47), and one patient died
of gastrointestinal cytomegalovirus infection (patient
#48). Using ABH immunohistochemistry on samples
from the skin (4 patients), heart (3 patients), bone marrow
(2 patients) and liver (1 patient), and additional in situ
hybridization for X and Y chromosomes in heart tissue of
two patients, endothelial cells from blood vessels in skin,
heart, liver and solid bone marrow showed no evidence
of donor-type endothelial cell chimerism (Table 1, Online
Supplementary Figure S1).
Discussion
This study provides evidence that replacement of
endothelial cells by bone marrow-derived donor stem
cells does not represent a major repair mechanism for
blood vessels after allogeneic HSCT. Overall, donor-
derived cells did not engraft systematically into the recip-
ient’s endothelium after HSCT, despite the presence of
donor-derived hematopoiesis. The results of endothelial
cell chimerism in animal models are controversial,
although recently published reports are in line with our
findings,25-28 and reports regarding humans remain scarce.
So far, endothelial cell chimerism has not been analyzed
after ABO-incompatible HSCT, but it has been described
after gender-mismatched HSCT. Two earlier studies,
which did not find donor-type endothelial cells in the
stromal constituents of bone marrow up to 3 years after
HSCT,29,30 were contrasted by several reports showing
endothelial cell chimerism in skin, gut, heart and bone
marrow after gender-mismatched HSCT.14-18,31,32 All these
studies used XY in situ hybridization for the detection of
donor-derived cells. Reported numbers of donor-type
bone marrow-derived endothelial cells after HSCT varied
from 2% in non-GVHD-affected skin and gastrointestinal
tract up to 40% in the lung. In any case, the detection of
endothelial cell chimerism depends crucially on the meth-
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Figure 1. (A) Representative
picture of the STR analysis
of DNA isolated from 40
endothelial cells from a skin
biopsy from a 27-year-old
female (patient #16), who
was treated for osteomyelofi-
brosis with hematopoietic
stem cells from her brother.
Skin biopsy 100 days post-
HSCT. Four STR loci (THO1,
TPOX, CSF1PO and amelo-
genin) are shown. (B) STR
pattern of the recipient
determined pre-HSCT. (C)
STR pattern of the donor
determined pre-HSCT.
A
B
C
CSF1P0
CSF1P0
CSF1P0
1200
800
400
0
1200
800
400
0
1200
800
400
0
TPOX
TPOX
TPOX
THO1
THO1
THO1
Amelogenin
X
X
Y
X
9
99.3
108
9
99.3
9.36 9
10
12
108
Amelogenin
Amelogenin
ods applied for chimerism analysis.
X and Y chromosome analysis by in situ hybridization
is generally performed in combination with immunohis-
tochemical staining of a single endothelial cell marker
such as CD31, CD34 or VWF, with potential pitfalls. In
our experience, several immunohistochemical endothelial
and hematopoietic cell markers, a careful morphological
analysis and XY in situ hybridization are necessary to con-
clusively determine endothelial cell chimerism. For
instance, CD34 is expressed not only on endothelial cells
but also on hematopoietic precursor cells and, without
leukocyte-specific CD45 staining,33 perivascular cells dis-
located into the luminal part of the vessels and extravasat-
ing or adhering leukocytes (in particular monocytes)
could be misinterpreted as endothelial cells. In addition,
cell morphology is often severely impaired due to the pre-
treatment (heat, enzyme digestion) of the tissue required
for XY in situ hybridization. 
ABH immunohistochemistry may also have several
technical and biological limitations. The levels of expres-
sion of ABH antigens may vary in different tissues and
vessels within the same patient, but there is also a consid-
erable inter-patient variability.24 In our study, samples
were obtained from both normal skin and from skin sus-
pected of having GVHD; the observed inter-patient vari-
ability may, therefore, be due to a loss of vessels and to
denudation of the vessel wall depending on the grade of
GVHD.34
In the present study we combined three different meth-
ods, i.e. immunohistochemical staining, XY in situ
hybridization and STR analysis. The STR analysis consis-
tently detected DNA with recipient-specific pattern in
endothelial cells and DNA with a donor-specific pattern
in blood cells; third-party DNA was never detected.
Moreover, no cells with more than diploid sex chromo-
somes were detected in any tissue specimen analyzed by
XY in situ hybridization, making cell fusion unlikely.12,13
Low-level endothelial cell chimerism was observed in
two patients who received grafts with minor ABO-incom-
patibility (O in A), although this finding could not be con-
firmed by XY in situ hybridization. Alternative explana-
tions for this apparent chimerism are invading leukocytes
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Figure 2. ABH antigen expression in skin biopsies. (A-D) Representative pictures from ABH antigen (Ag)-stained skin biopsy sections. (A) 46-
year old patient (#2) 151 days after minor ABO-incompatible HSCT (O in A). (B) 34-year old patient (#12) 94 days after minor ABO-incom-
patible HSCT (O in B). (C) 26-year old patient (#17) 718 days after major ABO-incompatible HSCT (B in O). (D) 28-year old patient (#40)
3,476 days after minor ABO-incompatible HSCT (A in AB). (E-H) Quantification of ABH Ag-positive endothelial cells in biopsies derived from
25 patients after ABO-incompatible HSCT. The number of ABH Ag-expressing endothelial cells is shown as the ratio to the number of counted
blood vessels in the same tissue section (y-axis). (E) B or O donor in A recipient, n=10. (F) A or O donor in B recipient, n=5. (G) A or B donor
in O recipient, n=6. (H) A or B donor in AB recipient, n=4. Ag: antigen; EC: Endothelial cells. 
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or altered ABH antigen expression caused by changes in A
and B glycosyltransferases due to leukemia.35 The amount
of CD45-positive leukocytes counted in the two skin biop-
sies was not higher than in other samples without
endothelial cell chimerism. However, H antigen expression
was also seen in skin biopsies of blood group type A
obtained from two patients before HSCT. In addition,
aberrant ABH antigen expression was seen in three
patients after ABO-identical HSCT. Patient #9 (A in A)
showed A and H antigens, patient #30 (A in A) showed A
and B antigens and patient #38 (O in O) showed H and B
antigens. This could be explained by genetic mutations of
the ABO-gene and/or aberrant ABH antigen expression, a
phenomenon described previously in rejection sites after
liver transplantation or in gastric and colonic tumors of
blood group O individuals.36,37 
Murata et al.17 elegantly demonstrated cells of donor-
specific male XY karyotype concurrently determined as
CD31-positive and CD45-negative endothelial cells in
GVHD-affected dermis of 13 gender-mismatched trans-
planted patients. Strikingly, the maximal percentage of
chimeric endothelial cells was 9.5% during the effector
phase of acute GVHD, but, after this phase, the propor-
tion of chimeric cells fell to 2%. Furthermore, Willemeze
et al.18 recently reported even higher percentages of donor-
derived endothelial cell chimerism (up to 25% in skin
biopsies) related to both repair of damaged endothelium
and maintenance of vascular homeostasis; in contrast,
skin epithelial cell chimerism (85%) did not seem to cor-
relate with tissue damage. 
In the present study, endothelial cell chimerism was
detected at lower levels (0.9% and 3.3%) in two out of 43
patients with skin biopsies (#25 and #28), and in none out
of five patients examined post-mortem after HSCT. Both
patients with endothelial cell chimerism suffered from
limited chronic GVHD at the time of the biopsy and had
a history of mild acute GVHD (grade I and grade II,
respectively), but no histological signs of skin inflamma-
tion or skin GVHD on the biopsy. In general, when all 46
histological samples examined for endothelial cell
chimerism by ABO were also analyzed for the presence
of skin GVHD, only 12 revealed signs of acute (n=3) or
chronic (n=9) GVHD. On the other hand, 45 patients of
the total study population of 52 had a history of clinically
determined GVHD (positive score for skin, gut and liver
manifestations) as noted in Table 1. Due to these low
numbers an association of donor endothelial chimerism
with GVHD could not be analyzed statistically. Taken
together, our results indicate that GVHD does not result
in widespread endothelial cell destruction, at least not in
the skin, as observed in hyperacute rejection in solid-
organ transplantation, yet the exact mechanism of
immunological escape after HSCT remains unexplained.34 
Analysis of tumor tissue arising after HSCT revealed
detectable amounts, i.e. 1.2% and 2.5%, of donor-derived
endothelial cells incorporating into the growing vascular
bed of the recipients. In line with this result, Peters et al.
also reported that secondary tumors after HSCT can
induce mobilization of bone marrow-derived stem cells
to areas of neovascularization.38 They showed that 4.9%
of the analyzed human tumor endothelial cells were of
bone marrow origin.38 Similarly, mouse models showed
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Figure 3. FISH in endothelial cells after gender-mismatched HSCT. FISH shows the X chromosome marked with CEP X Spectrum Green (green,
left column) and the Y chromosome with CEP Y Spectrum Red (red, middle column). Endothelial cells are stained for VWF (blue). Overlays of
the three different channels are shown in the right column. (A) Skin biopsy from a 59-year old male patient (#42), who was treated for myelodys-
plastic syndrome with hematopoietic stem cells from a female donor. Biopsy 188 days post-HSCT. Endothelial cells show recipient-specific XY
karyotype (arrows). (B) Mucoepidermoid carcinoma of the parotid gland from a 26-year old female patient (#50) who was treated for chronic
myeloid leukemia with hematopoietic stem cells from a male donor 12 years earlier. Hematopoietic cells show donor-specific XY karyotype
(arrowheads), whereas endothelial cells show recipient-specific XX karyotype (arrow).
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